Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Neurology
Erschienen in:

17.06.2022 | Neuromuscular Disorders (C Fournier, Section Editor)

Update on Paraneoplastic Neuromuscular Disorders

verfasst von: Andrés M. De León, MD, Taylor B. Harrison, MD, Rocio Garcia-Santibanez, MD

Erschienen in: Current Treatment Options in Neurology | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To review the clinical presentation and diagnosis of different paraneoplastic neuromuscular disorders and the available data on their treatment.

Recent Findings

Paraneoplastic neuromuscular disorders are rare, and their treatment needs a multidisciplinary approach. Given their rarity, there are no clinical trials specifically looking at these disorders and thus treatment is guided by management of autoimmune neuromuscular syndromes.

Summary

Paraneoplastic neuromuscular disorders can affect the entire axis of the peripheral nervous system including disorders of muscle, neuromuscular junction, peripheral nerve, and the sensory or motor neurons. Early detection and treatment of the underlying malignancy is key to the effective management of these conditions. Immune therapy can be offered but the evidence is strongest for treatment of muscle and neuromuscular junction diseases. Additional research is needed to better understand and treat paraneoplastic disorders of the nerves as well as the sensory and motor neurons.
Literatur
1.
•• Graus F, Vogrig A, Muñiz-Castrillo S, Antoine JCG, Desestret V, Dubey D, Giometto B, Irani SR, Joubert B, Leypoldt F, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflammation. 2021;8:e1014. Proposed new diagnostic criteria for diagnosis of paraneoplastic neurologic syndromes by a group of experts.
2.
Zoccarato M, Grisold W, Grisold A, Poretto V, Boso F, Giometto B. Paraneoplastic Neuropathies: What’s New Since the 2004 Recommended Diagnostic Criteria. Front Neurol. 2021;12:706169.PubMedPubMedCentralCrossRef
3.
Antoine JC, Camdessanché JP. Treatment options in paraneoplastic disorders of the peripheral nervous system. Curr Treat Options Neurol. 2013;15:210–23.PubMedCrossRef
4.
5.
Keime-Guibert F, Graus F, Broët P, Reñé R, Molinuevo JL, Ascaso C, Delattre JY. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology. 1999;53:1719–23.PubMedCrossRef
6.
• Goyal NA. Immune-Mediated Myopathies Continuum (Minneap Minn). 2019;25:1564–85. Review article on the different immune myopathies including the ones associated with malignancies.
7.
Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010;67:330–5.PubMedCrossRef
8.
Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013;65:2954–62.PubMedPubMedCentralCrossRef
9.
Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, Danoff SK, Johnson C, Christopher-Stine L, Mammen AL. Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care Res. 2017;69:1771–6.CrossRef
10.
Gono T, Kuwana M. Dermatomyositis-Associated Autoantibodies: TIF1-γ, NXP2, and MDA5. In Managing Myositis. Edited by: Springer International Publishing. 2020;193–198.
11.
Amato AA, Russell JA. Neuromuscular Disorders edn 2nd: McGraw Hill. 2016.
12.
Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, Callen JP, Fiorentino D. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts. Medicine (Baltimore). 2018;97: e9639.CrossRef
13.
Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PAE, Tanasescu R, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol. 2011;18:19-e13.PubMedCrossRef
14.
Selva-O’Callaghan A, Grau JM, Gámez-Cenzano C, Vidaller-Palacín A, Martínez-Gómez X, Trallero-Araguás E, Andía-Navarro E, Vilardell-Tarrés M. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med. 2010;123:558–62.PubMedCrossRef
15.
Mckeon A. Positron Emission Tomography-Computed Tomography in Paraneoplastic Neurologic Disorders. Arch Neurol. 2010;67:322.PubMedCrossRef
16.
Lancaster E. Paraneoplastic Disorders. CONTINUUM: Lifelong Learn Neurol. 2015;21:452–475.
17.
Kang EH, Lee SJ, Ascherman DP, Lee YJ, Lee EY, Lee EB, Song YW. Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatology. 2016;55:1631–41.PubMedCrossRef
18.
Dalakas MC. Immunotherapy of Inflammatory Myopathies: Practical Approach and Future Prospects. Curr Treat Options Neurol. 2011;13:311–23.PubMedCrossRef
19.
Bunch TW. Prednisone and azathioprine for polymyositis. Long-term followup Arthritis & Rheumatism. 1981;24:45–8.CrossRef
20.
Vencovsky J. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29:95–102.PubMedCrossRef
21.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–7.PubMedCrossRef
22.
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403–7.PubMedCrossRef
23.
Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: Present approaches and a look to the future. Neuromuscul Disord. 2006;16:223–36.PubMedCrossRef
24.
Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. 2018;28:913–21.PubMedCrossRef
25.
Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, Kawaguchi Y, Jinnin M, Muro Y, Ishihara S, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Mod Rheumatol. 2019;29:1–19.PubMedCrossRef
26.
Distad BJ, Amato AA, Weiss MD. Inflammatory Myopathies. Curr Treat Options Neurol. 2011;13:119–30.PubMedCrossRef
27.
Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51:638–56.PubMedCrossRef
28.
Raghu P, Manadan AM, Schmukler J, Mathur T, Block JA. Pulse Dose Methylprednisolone Therapy for Adult Idiopathic Inflammatory Myopathy. Am J Ther. 2015;22:244–7.PubMedCrossRef
29.
van de Vlekkert J, Hoogendijk JE, de Haan RJ, Algra A, van der Tweel I, van der Pol WL, Uijtendaal EV, de Visser M. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord. 2010;20:382–9.PubMedCrossRef
30.
Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, Mccrosky S. A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis. N Engl J Med. 1993;329:1993–2000.PubMedCrossRef
31.
Gelardi C, Paolini L, Danieli MG. Subcutaneous immunoglobulin G in idiopathic inflammatory myopathies: therapeutic implications. Isr Med Assoc J. 2014;16:646–7.PubMed
32.
Hachulla E, Benveniste O, Hamidou M, Mouthon L, Schleinitz N, Lozeron P, Léger JM, Vial C, Viala K. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. Int J Neurosci. 2017;127:516–23.PubMedCrossRef
33.
34.
Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, Thornton BC, Burgess SH, Plotz PH, Miller FW. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 1998;41:392–9.PubMedCrossRef
35.
Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med. 1980;92:365–369.
36.
Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129–37.PubMedCrossRef
37.
Witte AS, Cornblath DR, Schatz NJ, Lisak RP. Monitoring azathioprine therapy in myasthenia gravis. Neurology. 1986;36:1533–4.PubMedCrossRef
38.
Thomas CW, Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis. 2003;9:237–45.PubMedCrossRef
39.
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314–24.PubMedPubMedCentralCrossRef
40.
Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology. 2017;56:26–36.PubMedCrossRef
41.
Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, Van Assen S, Bijl M, Breedveld FC, D’Amelio R, Dougados M, Kapetanovic MC, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79:39–52.PubMedCrossRef
42.
Boekel L, Wolbink GJ. Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients. The Lancet Rheumatol. 2021.
43.
Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Allenbach Y, Amato A, Aussey A, Benveniste O, De Bleecker J, De Groot I, et al. 224th ENMC International Workshop: Neuromuscular Disorders. 2018;28:87–99.
44.
Lim J, Rietveld A, De Bleecker JL, Badrising UA, Saris CGJ, Van Der Kooi AJ, De Visser M. Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurology - Neuroimmunology Neuroinflammation. 2019;6: e513.PubMedCrossRef
45.
Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16:689–701.PubMedCrossRef
46.
Liu R, Fenves AZ, Champion SN, Dau J. Seronegative necrotizing autoimmune myopathy with favorable response to intravenous immunoglobulin. Baylor University Medical Center Proceedings. 2021;34:481–3.PubMedPubMedCentralCrossRef
47.
Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021;80:36–48.PubMedCrossRef
48.
Chiou-Tan FY, Gilchrist JM. Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: Review of recent literature. Muscle Nerve. 2015;52:455–62.PubMedCrossRef
49.
Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893–902.PubMedCrossRef
50.
51.
Zhao Y, Shi J, Fan L, Hu D, Yang J, Zhao H. Surgical treatment of thymoma: an 11-year experience with 761 patients. Eur J Cardiothorac Surg. 2016;49:1144–9.PubMedCrossRef
52.
Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: Association of British Neurologists’ management guidelines. Pract Neurol. 2015;15:199–206.PubMedCrossRef
53.
Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87:419–25.PubMedPubMedCentralCrossRef
54.
Gamez J, Salvadó M, Carmona F, De Nadal M, Romero L, Ruiz D, Jáuregui A, Martínez O, Pérez J, Suñé P, et al. Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis. Ther Adv Neurol Disord. 2019;12:175628641986449.CrossRef
55.
• Álvarez-Velasco R, Gutiérrez-Gutiérrez G, Trujillo JC, Martínez E, Segovia S, Arribas-Velasco M, Fernández G, Paradas C, Vélez-Gómez B, Casasnovas C, et al. Clinical characteristics and outcomes of thymoma-associated myasthenia gravis. Eur J Neurol. 2021;28:2083–91. Retrospective review of clinical features and prognosis of patients with thymomatous myasthenia gravis.PubMedCrossRef
56.
Wei ML, Kang D, Gu L, Qiu M, Zhengyin L, Mu Y. Chemotherapy for thymic carcinoma and advanced thymoma in adults. Cochrane Database Syst Rev. 2013.
57.
Medicine AQACAAoE. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve. 2001;24:1236–1238.
58.
Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. The Lancet Neurol. 2011;10:1098–107.PubMedCrossRef
59.
Titulaer MJ, Maddison P, Sont JK, Wirtz PW, Hilton-Jones D, Klooster R, Willcox N, Potman M, Sillevis Smitt PA, Kuks JB, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29:902–8.PubMedCrossRef
60.
61.
Nakao YK, Motomura M, Fukudome T, Fukuda T, Shiraishi H, Yoshimura T, Tsujihata M, Eguchi K. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology. 2002;59:1773–5.PubMedCrossRef
62.
Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1995;58:85–7.PubMedPubMedCentralCrossRef
63.
Lennon VA, Kryzer TJ, Griesmann GE, O’Suilleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert EH. Calcium-Channel Antibodies in the Lambert-Eaton Syndrome and Other Paraneoplastic Syndromes. N Engl J Med. 1995;332:1467–75.PubMedCrossRef
64.
Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology. 2000;54:603–7.PubMedCrossRef
65.
Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011.
66.
Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, Alsharabati M, Dimachkie M, Blanco JM, Brannagan T, Lavrnić D, Shieh PB, Vial C, et al. Amifampridine phosphate (Firdapse®) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve. 2016;53:717–25.PubMedCrossRef
67.
Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47:678–83.PubMedCrossRef
68.
Kimura I, Ayyar DR. The Eaton-Lambert myasthenic syndrome and long-term treatment with prednisolone. Tohoku J Exp Med. 1984;143:405–8.PubMedCrossRef
69.
Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology. 2000;54:2176–8.PubMedCrossRef
70.
Dubey D, Lennon VA, Gadoth A, Pittock SJ, Flanagan EP, Schmeling JE, McKeon A, Klein CJ. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology. 2018;90:e103–10.PubMedCrossRef
71.
Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, Chapuis F, Aguera M, Decullier E, Duchemin AM, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2009;80:412–6.PubMedCrossRef
72.
Glazebrook K, Guerra Bonilla FL, Johnson A, Leng S, Dispenzieri A. Computed tomography assessment of bone lesions in patients with POEMS syndrome. Eur Radiol. 2015;25:497–504.PubMedCrossRef
73.
Dyck PJ, Sherman WR, Hallcher LM, John Service F, O’Brien PC, Grina LA, Palumbo PJ, Swanson CJ. Human diabetic endoneurial sorbitol, fructose, andmyo-inositol related to sural nerve morphometry. Ann Neurol. 1980;8:590–6.CrossRef
74.
Naddaf E, Mauermann ML. Peripheral Neuropathies Associated With Monoclonal Gammopathies. Continuum (Minneap Minn). 2020;26:1369–83.
75.
Vernino S. Antibody testing as a diagnostic tool in autonomic disorders. Clin Auton Res. 2009;19:13–9.PubMedCrossRef
76.
Golden EP, Vernino S. Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances. Clin Auton Res. 2019;29:277–88.PubMedCrossRef
77.
Cheshire WP. Autonomic History, Examination, and Laboratory Evaluation. Continuum (Minneap Minn). 2020;26:25–43.
78.
Kaur D, Tiwana H, Stino A, Sandroni P. Autonomic neuropathies. Muscle Nerve. 2021;63:10–21.PubMedCrossRef
79.
Vernino S. Autoimmune Autonomic Disorders Continuum (Minneap Minn). 2020;26:44–57.
80.
Palma J-A, Kaufmann H. Management of Orthostatic Hypotension. CONTINUUM: Lifelong Learn Neurol. 2020;26:154–177.
81.
Hutto SK, Harrison TB. Electrodiagnostic Assessment of Hyperexcitable Nerve Disorders. Neurol Clin. 2021;39:1083–96.PubMedCrossRef
82.
Vernino S, Lennon VA. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve. 2002;26:702–7.PubMedCrossRef
83.
84.
Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis. Morvan’s syndrome and acquired neuromyotonia Brain. 2010;133:2734–48.PubMed
85.
Elangovan C, Morawo A, Ahmed A. Current Treatment Options for Peripheral Nerve Hyperexcitability Syndromes. Curr Treatment Options Neurol. 2018;20.
86.
Sawlani K, Katirji B. Peripheral Nerve Hyperexcitability Syndromes Continuum (Minneap Minn). 2017;23:1437–50.
87.
Merchut MP. Management of Voltage-Gated Potassium Channel Antibody Disorders. Neurol Clin. 2010;28:941–59.PubMedCrossRef
88.
89.
Camdessanche J-P, Jousserand G, Ferraud K, Vial C, Petiot P, Honnorat J, Antoine J-C. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain. 2009;132:1723–33.PubMedPubMedCentralCrossRef
90.
Camdessanché J-P, Jousserand G, Franques J, Pouget J, Delmont E, Créange A, Kuntzer T, Maisonobe T, Abba K, Antoine J-C. A clinical pattern-based etiological diagnostic strategy for sensory neuronopathies: a French collaborative study. J Peripher Nerv Syst. 2012;17:331–40.PubMedCrossRef
91.
Sharp L, Vernino S. Paraneoplastic neuromuscular disorders. Muscle Nerve. 2012;46:839–40.CrossRef
92.
Antoine JC, Robert-Varvat F, Maisonobe T, Créange A, Franques J, Mathis S, Delmont E, Kuntzer T, Lefaucheur JP, Pouget J, et al. Identifying a therapeutic window in acute and subacute inflammatory sensory neuronopathies. J Neurol Sci. 2016;361:187–91.PubMedCrossRef
93.
Antoine JC, Camdessanché JP. Paraneoplastic neuropathies. Curr Opin Neurol. 2017;30:513–20.PubMedCrossRef
94.
Graus F, Bonaventura I, Uchuya M, Valls-Sole J, Rene R, Leger JM, Tolosa E, Delattre JY. Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology. 1994;44:2258–2258.PubMedCrossRef
95.
Verschueren A, Gallard J, Boucraut J, Honnorat J, Pouget J, Attarian S. Paraneoplastic subacute lower motor neuron syndrome associated with solid cancer. J Neurol Sci. 2015;358:413–6.PubMedCrossRef
96.
Diamanti L, Quaquarini E, Berzero G, Bini P, Gastaldi M, Franciotta D, Alfonsi E, Ceroni M, Frascaroli M, Bernardo A, et al. Lower motor neuron syndrome in a patient with HER2-positive metastatic breast cancer: A case report and review of the literature. Clin Neurol Neurosurg. 2018;172:141–2.PubMedCrossRef
97.
Forsyth PA, Dalmau J, Graus F, Cwik V, Rosenblum MK, Posner JB. Motor neuron syndromes in cancer patients. Ann Neurol. 1997;41:722–30.PubMedCrossRef
98.
Ferracci F, Fassetta G, Butler MH, Floyd S, Solimena M, De Camilli P. A novel antineuronal antibody in a motor neuron syndrome associated with breast cancer. Neurology. 1999;53:852–5.PubMedCrossRef
99.
Kleinschmidt-Demasters BK, Marshall CB, Cykowski MD. Paraneoplastic Lower Motor Neuron Disease. J Neuropathol Exp Neurol. 2021;80:1125–7.PubMedCrossRef
100.
Goodfellow J, Gorrie G, Leach V, Patel S, Mackay G. Cancer and motor neuron disease—causal or coincidental? Two contrasting cases Neurological Sciences. 2019;40:1461–3.PubMed
101.
Verma A, Berger JR, Snodgrass S, Petito C. Motor neuron disease: A paraneoplastic process associated with anti-Hu antibody and small-cell lung carcinoma. Ann Neurol. 1996;40:112–6.PubMedCrossRef
102.
Distad BJ, Weiss MD. Paraneoplastic motor neuron disease associated with Purkinje cell autoantibody type 1. J Clin Neuromuscul Dis. 2010;12:36–41.PubMedCrossRef
103.
Struck AF, Salamat S, Waclawik AJ. Motor neuron disease with selective degeneration of anterior horn cells associated with non-Hodgkin lymphoma. J Clin Neuromuscul Dis. 2014;16:83–9.PubMedCrossRef
104.
Mélé N, Berzero G, Maisonobe T, Salachas F, Nicolas G, Weiss N, Beaudonnet G, Ducray F, Psimaras D, Lenglet T. Motor neuron disease of paraneoplastic origin: a rare but treatable condition. J Neurol. 2018;265:1590–9.PubMedCrossRef
Metadaten
Titel
Update on Paraneoplastic Neuromuscular Disorders
verfasst von
Andrés M. De León, MD
Taylor B. Harrison, MD
Rocio Garcia-Santibanez, MD
Publikationsdatum
17.06.2022
Verlag
Springer US
Erschienen in
Current Treatment Options in Neurology / Ausgabe 7/2022
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-022-00722-7

Weitere Artikel der Ausgabe 7/2022

Correction to: Acute Stroke Treatment in Children: Are Adult Guidelines Applicable?

  • Correction

Correction to: Options in the Treatment of Subacute Sclerosing Panencephalitis: Implications for Low Resource Areas

  • Open Access
  • Correction

Pharmacologic and Acute Management of Spinal Cord Injury in Adults and Children

  • Open Access
  • Critical Care Neurology (H Hinson, Section Editor)

Evaluation and Management of Delirium in Dementia

  • Dementia (J Pillai, Section Editor)

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

In 4% der in der Notfallambulanz initiierten zerebralen Bildgebung sind „alte“ Schlaganfälle zu erkennen. Gar nicht so selten handelt es sich laut einer aktuellen Studie dabei um unbemerkte Insulte. Bietet sich hier womöglich die Chance auf ein effektives opportunistisches Screening?

CGRP-Antikörper auch bei älteren Migränekranken sicher

Beginnen ältere Migränekranke eine Prophylaxe mit CGRP-Antikörpern, kommt es anschließend nicht häufiger zu kardiovaskulären Problemen als unter einer Prophylaxe mit Botulinumtoxin. Darauf deutet eine US-Analyse von Medicare-Versicherten.

Frühwarnzeichen für multiple Sklerose bei Kindern und Jugendlichen

Ein Forschungsteam aus Deutschland und Kanada hat eine Reihe metabolischer, okulärer, muskuloskelettaler, gastrointestinaler und kardiovaskulärer Symptome identifiziert, die bei Kindern und Jugendlichen der Diagnose einer multiplen Sklerose (MS) vorausgehen können.

Migräne verstehen und psychotherapeutisch behandeln

Das Wissen über die Mechanismen, die im Gehirn bei einer Migräneattacke ablaufen, und mögliche Auslöser wird immer breiter. Der psychologische Psychotherapeut Dr. Dipl.-Psych. Timo Klan fasst den aktuellen Erkenntnisstand zusammen. Und er gibt Tipps für eine differenzierte, individuelle Diagnostik auch von Begleiterkrankungen und beschreibt erfolgreiche psychotherapeutische Interventionen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise